Drugs / CD33 CAR-NK cell
last change Jan 2025 re-read 3 minutes ago

CD33 CAR-NK cell

Cell therapy targets CD33

Developed for
acute myeloid leukemia
Investigated by
Hangzhou Qihan Biotech Co., Ltd. · Institute of Hematology & Blood Diseases Hospital, China

Trials 1

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05987696 Jul 2023 → Jan 2025 acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CD33 CAR-NK cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT05987696 ↗
Modality Cell therapy “CD33 CAR-NK cell” NCT05987696 ↗
Target CD33 “CD33 CAR-NK cell” NCT05987696 ↗